Latest News on AQST

Financial News Based On Company


Advertisement
Advertisement

Aquestive Therapeutics to Present at Piper Sandler 38th Annual Healthcare Conference

https://www.quiverquant.com/news/Aquestive+Therapeutics+to+Present+at+Piper+Sandler+38th+Annual+Healthcare+Conference%0A
Aquestive Therapeutics will participate in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, where President and CEO Daniel Barber will present on December 2 at 10:30 am ET. The company is advancing innovative medicines like Anaphylm™ for severe allergic reactions and AQST-108 for dermatological conditions, utilizing its PharmFilm® technology. A webcast of the presentation will be available on their website, with a replay offered for 30 days.

Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference

https://www.globenewswire.com/news-release/2026/11/18/3405512/0/en/aquestive-therapeutics-to-present-at-the-piper-sandler-38th-annual-healthcare-conference.html
Aquestive Therapeutics, Inc. announced that its management team will participate in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. President and CEO Daniel Barber is scheduled to present on December 2, 2026, at 10:30 am ET, with the company also hosting one-on-one investor meetings. A webcast of the presentation will be available on the company’s investor relations website.

Aquestive Therapeutics at Jefferies conference: anaphylm drives growth

https://www.investing.com/news/transcripts/aquestive-therapeutics-at-jefferies-conference-anaphylm-drives-growth-93CH-5028856
Aquestive Therapeutics presented at the Jefferies Global Healthcare Conference, highlighting its oral thin film technology and the lead epinephrine product, Anaphylm. The company outlined a growth plan based on strong clinical data, a solid cash position of approximately $185 million for a U.S. launch, and a large, underpenetrated market for anaphylaxis. Anaphylm, a needle-free epinephrine film, has an FDA action date of March 16, 2027, with a planned U.S. launch in spring 2027 if approved.

Aquestive Therapeutics (AQST) officer Davis sells 7,197 shares under a preset trading plan.

https://www.stocktitan.net/sec-filings/AQST/form-4-aquestive-therapeutics-inc-insider-trading-activity-860f51d52552.html
Matthew W. Davis, Chief Development Officer of Aquestive Therapeutics (AQST), sold 7,197 shares of common stock on November 12, 2026. The shares were sold at a weighted average price of $3.5468 per share, ranging from $3.46 to $3.64, as part of a Rule 10b5-1 trading plan. Following the transaction, Davis directly holds 87,500 shares of the company.

AQST: Aquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

https://www.quantisnow.com/insight/aquestive-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6792062
Aquestive Therapeutics Inc. filed an SEC Form 8-K, furnishing an investor presentation for the Jefferies Global Healthcare Conference held on November 16, 2026. The presentation highlighted the company's cash position of $90.3 million as of September 30, 2026, and the upcoming PDUFA goal date of March 16, 2027, for its drug Anaphylm. Potential future funding of up to $75 million from RTW and $20 million from Oaktree is contingent on Anaphylm's FDA approval.
Advertisement

AQST: Anaphylm targets a spring 2027 U.S. launch after its March FDA action date

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4637196:0-aqst-anaphylm-targets-a-spring-2027-u-s-launch-after-its-march-fda-action-date/
Aquestive Therapeutics' Anaphylm, an epinephrine auto-injector, has a resubmitted New Drug Application (NDA) with an FDA action date of March 16, 2027. The company is planning a U.S. launch for spring 2027 and has allocated nearly $200 million in launch resources. Management highlighted the product's clinical differentiation, commercial readiness, and the growing market for anaphylaxis treatments.

Form 4 Aquestive Therapeutics Inc: Matthew W. Davis (Chief Development Officer) For: 10 November

https://ng.investing.com/news/stock-market-news/form-4-aquestive-therapeutics-inc-matthew-w-davis-chief-development-officer-for-10-november-93CH-2808028
This article reports on a Form 4 filing for Aquestive Therapeutics Inc., specifically detailing a transaction by Matthew W. Davis, the Chief Development Officer. The filing pertains to activity on November 10, indicating insider transaction information.

Director Richard J. Daly buys 28,025 Aquestive Therapeutics (AQST) shares on the open market.

https://www.stocktitan.net/sec-filings/AQST/form-4-aquestive-therapeutics-inc-insider-trading-activity-ca887be93736.html
Aquestive Therapeutics, Inc. director Richard J. Daly reported purchasing 28,025 shares of common stock on November 10, 2026, through two direct open-market transactions. He bought 1,200 shares at $3.53 each and 26,825 shares at $3.545 each. Following these transactions, Daly's direct holdings in common stock increased from 0 to 28,025 shares.

Aquestive Therapeutics (AQST) director Daly bought 28,025 shares for $99.3K at an average $3.54

https://quantisnow.com/insight/director-daly-richard-j-bought-99331-worth-of-shares-28025-6787237
Richard J. Daly, a director at Aquestive Therapeutics (AQST), recently purchased 28,025 shares for approximately $99,300 at an average price of $3.54 per share. These open-market transactions, reported on November 10, 2026, increased his direct holdings in the company to 28,025 shares. This insider buying activity is seen as a signal of confidence by an executive in the company's prospects.

At $3.52 a share, Aquestive Therapeutics (AQST) withholds Davis’s stock to cover vesting taxes.

https://www.stocktitan.net/sec-filings/AQST/form-4-aquestive-therapeutics-inc-insider-trading-activity-efd419e136a5.html
Aquestive Therapeutics (AQST) reported that its Chief Development Officer, Matthew W. Davis, had 5,303 shares of common stock withheld by the company on November 10, 2026. This action was taken to satisfy tax withholding obligations related to the vesting of his previously granted restricted stock units, with a reported per-share value of $3.52. Following this transaction, Davis directly held 94,697 shares.
Advertisement

Aquestive Therapeutics (AQST) director Daly bought 28,025 shares for $99.3K at an average $3.54

https://www.quantisnow.com/insight/director-daly-richard-j-bought-99331-worth-of-shares-28025-6787237
Richard J. Daly, a director at Aquestive Therapeutics (AQST), purchased 28,025 shares of the company's common stock for approximately $99.3K at an average price of $3.54 per share on November 10, 2026. Following these open-market transactions, Daly directly holds 28,025 shares. This insider buying activity is reported via a Quantisnow filing, suggesting confidence from the director in the company's prospects.

Form 4 Aquestive Therapeutics Inc: Richard J. Daly (Director) For: 6 November

https://ca.investing.com/news/stock-market-news/form-4-aquestive-therapeutics-inc-richard-j-daly-director-for-6-november-93CH-4950788
This article reports on a Form 4 filing for Aquestive Therapeutics Inc., detailing a transaction involving Director Richard J. Daly on November 6. The content highlights the public disclosure of insider trading activity for the company, identified by the stock symbol AQST.

A director receives 57,000 stock options with a $3.61 exercise price at Aquestive (AQST).

https://www.stocktitan.net/sec-filings/AQST/form-4-aquestive-therapeutics-inc-insider-trading-activity-865e376bdee8.html
Aquestive Therapeutics, Inc. director Richard J. Daly was granted 57,000 non-qualified stock options on November 6, 2026, with an exercise price of $3.61 per share. These options will vest in three equal annual installments starting November 6, 2027, and will expire on November 6, 2036. This transaction increased Daly's direct holdings of non-qualified stock options from 0 to 57,000.

Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference

https://www.manilatimes.net/2026/11/09/tmt-newswire/globenewswire/aquestive-therapeutics-to-present-at-the-jefferies-global-healthcare-conference/2465133
Aquestive Therapeutics, Inc. (NASDAQ:AQST) announced that its management team will present at the Jefferies Global Healthcare Conference from November 16-19, 2026. The presentation is scheduled for November 16th at 10:00 am GMT, with a webcast available on the company's investor relations website. Management will also hold one-on-one meetings with investors on November 16th, 17th, and 18th.

Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference

https://finance.yahoo.com/healthcare/articles/aquestive-therapeutics-present-jefferies-global-120000376.html
Aquestive Therapeutics (NASDAQ:AQST) announced its management team will participate in the Jefferies Global Healthcare Conference from November 16-19, 2026. The company will deliver a presentation on November 16th at 10:00 am GMT and host one-on-one investor meetings. A webcast of the presentation will be available on Aquestive's investor relations website.
Advertisement

Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference

https://www.globenewswire.com/news-release/2026/11/09/3398247/0/en/aquestive-therapeutics-to-present-at-the-jefferies-global-healthcare-conference.html
Aquestive Therapeutics, Inc. announced its management team will present at the Jefferies Global Healthcare Conference from November 16-19, 2026, with a presentation scheduled for November 16th at 10:00 am GMT. The company will also host one-on-one investor meetings on November 16, 17, and 18. A webcast of the presentation will be available on Aquestive's investor relations website, with a replay accessible for 30 days.

What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call

https://es.tradingview.com/news/marketbeat:6e42b7a40094b:0
Aquestive Therapeutics (AQST) discussed its Q3 earnings, highlighting the resubmission of its Anaphylm application for FDA approval with a March 16, 2027, goal date, and preparations for a potential U.S. launch next year. The company also announced a licensing deal with Eton Pharmaceuticals for Libervant and provided updates on its financial results, including total third-quarter revenue of $7.6 million and a net loss of $16.5 million. Aquestive outlined its commercial strategy for Anaphylm, focusing on high epinephrine prescribers and leveraging clinical data for payer coverage.

Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...

https://ca.finance.yahoo.com/news/aquestive-therapeutics-inc-aqst-q3-190517438.html
Aquestive Therapeutics reported a Q3 2026 revenue of $7.6 million, down from $12.8 million in Q3 2025, primarily due to fluctuations in Suboxone product orders. Despite the revenue dip, the company highlighted progress with its Anifilm NDA resubmission, now with an FDA action date of March 16, 2027, and its strategic out-licensing of Libervant to Eton Pharmaceuticals. Aquestive also refinanced its debt, ending Q3 with $90.3 million in cash and expects to end 2026 with over $70 million, while preparing for Anifilm's potential U.S. launch.

With $90.3M cash at September 30, 2026, Aquestive (AQST) outlines funding tied to Anaphylm approval.

https://www.stocktitan.net/sec-filings/AQST/8-k-aquestive-therapeutics-inc-reports-material-event-f84e3b3b43ab.html
Aquestive Therapeutics reported having $90.3 million in cash and cash equivalents as of September 30, 2026, with additional funding sources contingent on the FDA approval of its investigational product, Anaphylm. The company's Class 2 NDA resubmission for Anaphylm has an FDA PDUFA goal date of March 16, 2027, and it is also targeting ex-U.S. filings for Canada by year-end 2026 and the European Union in Q1 2027. Aquestive estimates potential annual U.S. revenue for Anaphylm to exceed $1 billion, assuming regulatory approval and successful commercialization.

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting

https://www.globenewswire.com/news-release/2026/11/05/3396263/0/en/aquestive-therapeutics-to-present-data-at-the-2026-acaai-annual-meeting.html
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced that it will present data on its investigational product candidate Anaphylm™ (dibutepinephrine) sublingual film at the 2026 American College of Allergy, Asthma, and Immunology (ACAAI) Annual Meeting. The presentations will include oral and poster sessions highlighting the pharmacokinetic and pharmacodynamic profile of Anaphylm and healthcare provider perspectives on epinephrine delivery for anaphylaxis. Anaphylm aims to be the first and only oral rescue medication for severe allergic reactions if approved by the FDA.
Advertisement

Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting

https://www.manilatimes.net/2026/11/05/tmt-newswire/globenewswire/aquestive-therapeutics-to-present-data-at-the-2026-acaai-annual-meeting/2462819
Aquestive Therapeutics (NASDAQ: AQST) announced that it will present multiple oral and poster presentations at the 2026 American College of Allergy, Asthma, and Immunology (ACAAI) Annual Meeting. The presentations will highlight research on Anaphylm™ (dibutepinephrine) sublingual film, an investigational product candidate for severe allergic reactions, focusing on its pharmacokinetic and pharmacodynamic profile and healthcare provider perspectives on epinephrine delivery. If approved, Anaphylm would be the first and only oral rescue medication for anaphylaxis.

What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call

https://es.tradingview.com/news/marketbeat:6e42b7a40094b:0-what-aquestive-therapeutics-aqst-said-on-its-q3-earnings-call/
Aquestive Therapeutics (AQST) discussed its Q3 earnings, highlighting the resubmission of its Anaphylm application to the FDA with a goal date of March 16, 2027, and detailing launch preparations including sales force deployment and payer discussions. The company also announced a licensing deal for Libervant with Eton Pharmaceuticals, receiving an upfront payment and potential milestones. Financially, Aquestive reported a total third-quarter revenue of $7.6 million and a net loss of $16.5 million, while maintaining its 2026 revenue and EBITDA outlook.

Earnings call transcript: Aquestive Therapeutics misses Q3 2026 estimates

https://www.investing.com/news/transcripts/earnings-call-transcript-aquestive-therapeutics-misses-q3-2026-estimates-93CH-5000249
Aquestive Therapeutics reported a wider-than-expected Q3 2026 loss and revenue below Wall Street estimates, with an adjusted loss of $0.18 per share on $7.5 million in revenue. Despite the miss, the company's stock rose in after-hours trading, reflecting investor focus on regulatory progress for its lead drug candidate, Anaphylm, which received FDA resubmission acceptance with a PDUFA date of March 16, 2027. Aquestive maintained its full-year 2026 guidance and expects to end the year with over $70 million in cash.

What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:6e42b7a40094b:0-what-aquestive-therapeutics-aqst-said-on-its-q3-earnings-call/
Aquestive Therapeutics (AQST) announced the resubmission of its application for Anaphylm, an epinephrine sublingual film, with an FDA goal date of March 16, 2027, and is preparing for a potential U.S. launch next year. The company also highlighted a licensing deal with Eton Pharmaceuticals for Libervant, its diazepam buccal film, which includes an upfront payment and potential milestones. Aquestive reported a total third-quarter revenue of $7.6 million and a net loss of $16.5 million, maintaining its 2026 financial outlook.

AQST: Anaphylm advances toward a March 2027 FDA decision as Libervant brings $10 million upfront

https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:4262120:0-aqst-anaphylm-advances-toward-a-march-2027-fda-decision-as-libervant-brings-10-million-upfront/
Aquestive Therapeutics (AQST) has resubmitted the NDA for Anaphylm, setting a PDUFA goal date of March 16, 2027. The company's Q3 cash position was $90.3 million, bolstered by a $10 million upfront payment from the Libervant deal, and it projects 2026 revenue guidance between $46-$50 million.
Advertisement

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://investingnews.com/aquestive-therapeutics-reports-third-quarter-2026-financial-results-and-provides-business-update/
Aquestive Therapeutics announced its third-quarter 2026 financial results, highlighted by the FDA's acceptance of the Anaphylm resubmission with a PDUFA goal date of March 16, 2027. The company is advancing commercial preparations for Anaphylm, an oral epinephrine product for severe allergic reactions, and expects to file in Canada and the EU soon. Aquestive also reported decreased total revenues to $7.6 million from $12.8 million in Q3 2025 and a net loss of $16.5 million for the quarter.

Q3 revenue fell at Aquestive (AQST), while nine-month revenue included a $5M one-time royalty.

https://www.stocktitan.net/sec-filings/AQST/10-q-aquestive-therapeutics-inc-quarterly-earnings-report-71d84eff24f0.html
Aquestive Therapeutics (AQST) reported a 41% decrease in Q3 2026 revenue to $7.56 million compared to the prior year, primarily due to lower Suboxone sales. However, nine-month revenue increased 14% to $35.82 million, driven by a $5 million one-time royalty payment from Zevra Therapeutics. The company also announced that the FDA accepted its Anaphylm NDA resubmission with a PDUFA goal date of March 16, 2027.

Aquestive Therapeutics Inc. (AQST) Misses Q3 EPS by 6c

https://www.streetinsider.com/Earnings/Aquestive+Therapeutics+Inc.+%28AQST%29+Misses+Q3+EPS+by+6c/27281935.html
Aquestive Therapeutics Inc. (AQST) reported Q3 EPS of ($0.18), missing the analyst estimate of ($0.12) by $0.06. The company's revenue for the quarter was $7.5 million, which was below the consensus estimate of $11.02 million.

Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/11/03/3394752/0/en/aquestive-therapeutics-reports-third-quarter-2026-financial-results-and-provides-business-update.html
Aquestive Therapeutics reported its Q3 2026 financial results, highlighting a net loss of $16.5 million on total revenues of $7.6 million, a 41% decrease from the prior year. The company provided a business update on Anaphylm, its oral epinephrine product candidate, whose resubmission was accepted by the FDA with a PDUFA goal date of March 16, 2027, and noted progress on commercial preparations and international filings. Additionally, Aquestive discussed advancements in its AQST-108 topical gel program and a new commercialization agreement for Libervant with Eton Pharmaceuticals.

Aquestive Therapeutics, Inc. (AQST) Seasonal returns chart

https://uk.finance.yahoo.com/quote/AQST/seasonality/
The article provides a seasonal returns chart for Aquestive Therapeutics, Inc. (AQST), showing the average monthly price return from 2018 to 2026. It also includes current stock performance, upcoming earnings call information, and various financial data points for the company.
Advertisement

Aquestive Therapeutics, Inc. (AQST) Seasonal returns chart

https://au.finance.yahoo.com/quote/AQST/seasonality/
The article provides a seasonal returns chart for Aquestive Therapeutics, Inc. (AQST) via Yahoo Finance. However, it explicitly states that seasonality data is currently unavailable for AQST. The page also shows current stock performance and market data for various indices and commodities.

Aquestive Therapeutics, Inc. (AQST) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/AQST/seasonality/
This Yahoo Finance page provides a seasonal returns chart for Aquestive Therapeutics, Inc. (AQST). It displays the average monthly price return for the company's stock from 2018 to 2026. The current stock price for AQST is also listed, showing a slight decrease.

Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET

https://sg.finance.yahoo.com/news/aquestive-therapeutics-report-third-quarter-110000831.html
Aquestive Therapeutics, Inc. announced it will report its third-quarter 2026 financial results and provide business updates after market close on Tuesday, November 3, 2026. The company will also host a conference call for investors on Wednesday, November 4, 2026, at 8:00 a.m. ET. Investors can register for the call and access a live webcast and replay through the company's website.

Aquestive Therapeutics to Report Third Quarter 2026

https://www.globenewswire.com/news-release/2026/10/27/3388819/0/en/aquestive-therapeutics-to-report-third-quarter-2026-financial-results-and-recent-business-highlights-on-november-3-and-host-conference-call-on-november-4-at-8-00-a-m-et.html
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced it will report its third-quarter 2026 financial results and business updates after market close on Tuesday, November 3, 2026. The company will host a conference call for investors on Wednesday, November 4, 2026, at 8:00 a.m. ET to discuss these results. Aquestive Therapeutics is a biopharmaceutical company focused on innovative science and delivery technologies, including its Anaphylm™ and AQST-108 platforms.

Aquestive Therapeutics, Inc. Estimates – NASDAQ:AQST

https://www.tradingview.com/symbols/NASDAQ-AQST/financials-estimates/
This page on TradingView provides financial data and analyst estimates for Aquestive Therapeutics, Inc. (NASDAQ:AQST). Users can explore reported financial data across income statements, balance sheets, and cash flow statements, comparing actual results with average, high, and low estimates, and visualize trends over time. The platform emphasizes that the information is not investment advice and encourages users to conduct their own research.
Advertisement

Form 4 Aquestive Therapeutics Inc: John Cochran (Director) For: 21 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-aquestive-therapeutics-inc-john-cochran-director-for-21-october-93CH-4523306
This article from Investing.com reports a Form 4 filing for Aquestive Therapeutics Inc., indicating an insider transaction by Director John Cochran for October 21st. The brief update is relevant for investors tracking insider activity and regulatory disclosures for the company.

Form 4 Aquestive Therapeutics Inc: John Cochran (Director) For: 21 October

https://ng.investing.com/news/stock-market-news/form-4-aquestive-therapeutics-inc-john-cochran-director-for-21-october-93CH-2755196
This article reports that John Cochran, a Director at Aquestive Therapeutics Inc. (AQST), filed a Form 4 for activity on October 21st. The filing indicates insider transaction activity for the company, which saw its stock price decrease by 3.03%.

A 62,229-share transfer leaves Aquestive (AQST) director holding 161,715 shares directly.

https://www.stocktitan.net/sec-filings/AQST/form-4-aquestive-therapeutics-inc-insider-trading-activity-a39070c27ba2.html
Aquestive Therapeutics, Inc. (AQST) director John Cochran acquired 62,229 common shares through a transfer from Bratton Capital Management L.P. on October 21, 2026. Following this transaction, Cochran directly holds 161,715 shares of the company. No Rule 10b5-1 plan was reported for this transaction.

Aquestive Therapeutics Updates Bylaws to Streamline Stockholder Nomination Disclosures

https://kalkinemedia.com/us/news/announcements/aquestive-therapeutics-updates-bylaws-to-streamline-stockholder-nomination-disclosures
Aquestive Therapeutics, Inc. has amended its bylaws, effective October 15, 2026, to simplify stockholder nomination disclosure requirements. The key change removes the obligation for nominating stockholders to disclose relationships with individuals "acting in concert with" a proposed nominee. This revision also updates the definition of "Stockholder Associated Person" to exclude such individuals.

Board nomination rule changes took effect October 15 at Aquestive Therapeutics (AQST).

https://www.stocktitan.net/sec-filings/AQST/8-k-aquestive-therapeutics-inc-reports-material-event-bc53859b8a27.html
Aquestive Therapeutics (AQST) amended its bylaws, effective October 15, 2026, to revise requirements for stockholder nominations to the Board. The changes remove a requirement for disclosing certain relationships between nominating stockholders or Stockholder Associated Persons and individuals acting in concert with proposed nominees, their families, and affiliates. Additionally, the definition of "Stockholder Associated Person" was modified to exclude persons acting in concert with nominating stockholders.
Advertisement

Sidley Represents Aquestive Therapeutics in Exclusive U.S. Licensing Agreement With Eton Pharmaceuticals

https://legaldesire.com/sidley-represents-aquestive-therapeutics-in-exclusive-u-s-licensing-agreement-with-eton-pharmaceuticals/
Sidley represented Aquestive Therapeutics in an exclusive U.S. licensing and supply agreement with Eton Pharmaceuticals for Libervant® (diazepam) buccal film, a treatment for seizure clusters. This agreement grants Eton exclusive commercialization rights for Libervant in the U.S., targeting an estimated $450 million annual market, with a commercial launch anticipated in April 2027.

Richard J. Daly Submits Initial SEC Ownership Filing for Aquestive Therapeutics

https://kalkinemedia.com/us/news/announcements/richard-j-daly-submits-initial-sec-ownership-filing-for-aquestive-therapeutics
Richard J. Daly, a Director at Aquestive Therapeutics, Inc. (NASDAQ: AQST), has filed his initial SEC Statement of Beneficial Ownership. The filing, dated October 16, 2026, indicates that Daly holds no common stock directly or indirectly, and no derivative securities in the company as of October 15, 2026. This disclosure marks his initial ownership position upon joining the board.

Aquestive Therapeutics CEO sells $105,600 in shares

https://www.investing.com/news/insider-trading-news/aquestive-therapeutics-ceo-sells-105600-in-shares-93CH-4954735
The CEO of Aquestive Therapeutics, Daniel Barber, sold 25,000 shares of the company's common stock for a total of $105,600. The sale occurred on October 15, 2026, with shares transacting between $4.03 and $4.68. This transaction comes as the stock has declined 15% in the past week, though analysis suggests it may be undervalued.

Form 4 Aquestive Therapeutics Inc: Daniel Barber (Director, President and CEO) For: 15 October

https://ca.investing.com/news/stock-market-news/form-4-aquestive-therapeutics-inc-daniel-barber-director-president-and-ceo-for-15-october-93CH-4885765
This article reports on a Form 4 filing for Aquestive Therapeutics Inc., detailing insider transactions by Daniel Barber, who holds roles as Director, President, and CEO. The filing is specifically for transactions that occurred on October 15th.

CEO sells 25,000 shares under a trading plan at Aquestive (AQST).

https://www.stocktitan.net/sec-filings/AQST/form-4-aquestive-therapeutics-inc-insider-trading-activity-0210f7b24b85.html
Aquestive Therapeutics' President and CEO, Daniel Barber, sold 25,000 shares of common stock on October 15, 2026, under a Rule 10b5-1 plan. The shares were sold at a weighted average price of $4.2240, with transaction prices ranging from $4.03 to $4.68. Following the sale, Barber directly holds 627,317 shares.
Advertisement

Richard J. Daly reports no directly held common shares in Aquestive Therapeutics (AQST).

https://www.stocktitan.net/sec-filings/AQST/form-3-aquestive-therapeutics-inc-initial-statement-of-beneficial-own-d860c4b58921.html
Aquestive Therapeutics director Richard J. Daly has reported holding zero directly owned common shares in the company following an entry on October 15, 2026. This information was disclosed in a Form 3 filing, indicating an initial statement of beneficial ownership. The filing sentiment is neutral, reflecting a straightforward report of no direct holdings.

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

https://finance.yahoo.com/healthcare/articles/aquestive-therapeutics-announces-fda-acceptance-110000404.html
Aquestive Therapeutics announced that the FDA has accepted its New Drug Application (NDA) resubmission for Anaphylm™ (dibutepinephrine) sublingual film, assigning a PDUFA goal date of March 16, 2027. This acceptance follows positive results from recent studies addressing previous FDA concerns. If approved, Anaphylm would be the first oral rescue medication for severe allergic reactions, offering a new, convenient treatment option for patients.

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

https://www.globenewswire.com/news-release/2026/10/15/3381477/0/en/aquestive-therapeutics-announces-fda-acceptance-of-anaphylm-nda-resubmission-and-pdufa-goal-date-of-march-16-2027.html
Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm™ sublingual film and set a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first oral rescue medication for severe allergic reactions, including anaphylaxis. The company is also progressing with its ex-U.S. regulatory strategy, planning a Canadian NDS in Q4 2026.

FDA Sets March 16, 2027 PDUFA Date for Aquestive Therapeutics' Anaphylm NDA Resubmission

https://kalkinemedia.com/us/news/announcements/fda-sets-march-16-2027-pdufa-date-for-aquestive-therapeutics-anaphylm-nda-resubmission
Aquestive Therapeutics announced that the FDA has accepted its New Drug Application (NDA) resubmission for Anaphylm (dibutepinephrine) sublingual film as complete. The FDA has set a PDUFA target date of March 16, 2027, for the review of Anaphylm, which is designed to treat Type I allergic reactions, including anaphylaxis. This disclosure was made in an 8-K filing on October 15, 2026.

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

https://au.finance.yahoo.com/news/aquestive-therapeutics-announces-fda-acceptance-110000404.html
Aquestive Therapeutics announced that the FDA has accepted its resubmission of the New Drug Application (NDA) for Anaphylm™ (dibutepinephrine) sublingual film, assigning a PDUFA goal date of March 16, 2027. If approved, Anaphylm would be the first and only oral rescue medication for severe allergic reactions, including anaphylaxis. The company is also progressing with ex-U.S. regulatory efforts, planning a New Drug Submission to Health Canada in Q4 2026.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement